

COVID-19 IMPACT

This report has been affected by the COVID-19 pandemic. All forecasts and analysis have been revised to reflect the current view including the effect of the pandemic and associated recession.

RESEARCH REPORT



LIQUID BIOPSY MARKETS BY CANCER, USAGE, BIOMARKER, PLACE, & PRODUCT WITH PRICE AND VOLUME OUTLOOK. INCLUDING EXECUTIVE AND CONSULTANT GUIDES AND CUSTOMIZED FORECASTING AND ANALYSIS 2022-2026



Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the XRay market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

Table of Contents

- 1 Market Guides26
 - 1.1 Liquid Biopsy Market - Strategic Situation Analysis & Impact of COVID-19 27
 - 1.2 Guide for Executives, Marketing, Sales and Business Development Staff 29
 - 1.3 Guide for Management Consultants and Investment Advisors..... 31
- 2 Introduction and Market Definition32
 - 2.1 What is Liquid Biopsy? 33
 - 2.2 The Sequencing Revolution 34
 - 2.3 Market Definition 36
 - 2.3.1 Revenue Market Size 36
 - 2.4 Methodology..... 37
 - 2.4.1 Authors 37
 - 2.4.2 Sources 38
 - 2.5 Perspective: Healthcare, the IVD Industry, and the COVID-19 Pandemic 39
 - 2.5.1 Global Healthcare Spending 39
 - 2.5.2 Spending on Diagnostics 40
 - 2.5.3 Important Role of Insurance for Diagnostics 41
- 3 Market Overview42
 - 3.1 Players in a Dynamic Market..... 44
 - 3.1.1 Academic Research Lab 45

- 3.1.2 Diagnostic Test Developer..... 45
- 3.1.3 Genomic Instrumentation Supplier 45
 - 3.1.3.1 Cell Separation and Viewing Instrumentation Supplier..... 46
- 3.1.4 Pharmaceutical/Reagent Supplier..... 46
- 3.1.5 Independent Testing Lab..... 46
- 3.1.6 Public National/regional lab 47
- 3.1.7 Hospital lab 47
- 3.1.8 Physician Lab 47
- 3.1.9 Audit Body 48
- 3.1.10 Certification Body..... 48
- 3.2 Using Biopsies..... 50
 - 3.2.1 Cancer 50
 - 3.2.2 Precancerous conditions..... 51
 - 3.2.3 Inflammatory conditions..... 51
- 3.3 Biopsy Sites..... 52
- 3.4 The Situation Today – Biopsy Analysis 54
- 3.5 Evidence of Cancer - Liquid Biopsy Technology..... 55
 - 3.5.1 The Big Picture on Liquid Biopsy Technology 55
 - 3.5.2 The Role of CTCs..... 57
 - 3.5.2.1 Types of CTCs 58
 - 3.5.2.2 CellSearch Detection- Ultimate Sensitivity 59
 - 3.5.2.3 Epic Sciences Detection- Imaging Takes the Lead 59
 - 3.5.2.4 Maintrac Detection – The Microscope 60
 - 3.5.2.5 Other Methods..... 62

- 3.5.3 ctDNA – Going Mainstream? 63
- 3.5.4 Exosomes and Micro Vesicles – New Kid on the Block..... 64
- 3.5.5 The Multiple Play 67
- 3.6 Cancer Treatment Protocol Under Siege..... 69
 - 3.6.1 Issues to Liquid Biopsy Adoption – Double Diagnostics 69
 - 3.6.2 The Cancer Screening Market Opportunity..... 70
 - 3.6.2.1 GRAIL – What Is It? 71
 - 3.6.3 Cancer Management vs. Diagnosis 72
 - 3.6.3.1 The Role of Risk Assessment 72
 - 3.6.3.2 Managing Therapy 73
 - 3.6.3.3 Monitoring Disease – What Is It? 73
 - 3.6.4 Phases of Adoption – Looking into The Future 74
 - 3.6.5 The Promise of Liquid Biopsy 75
- 3.7 Structure of Industry Plays a Part..... 77
 - 3.7.1 Hospital Testing Share 77
 - 3.7.2 Economies of Scale..... 77
 - 3.7.2.1 Hospital vs. Central Lab..... 78
 - 3.7.3 Physician Office Lab's..... 79
 - 3.7.4 Physician's and POCT 79
- 4 Market Trends81
 - 4.1 Factors Driving Growth 82
 - 4.1.1 Non Invasive Game Changer 82
 - 4.1.2 Lower Cost 83
 - 4.1.3 Greater Accuracy 83

- 4.1.4 Wide Range of Potential Uses 83
- 4.1.5 Aging Population..... 83
- 4.2 Factors Limiting Growth 85
 - 4.2.1 Lower prices..... 85
 - 4.2.2 Lack of Standards 86
 - 4.2.3 Protocol Resistance..... 86
 - 4.2.4 Initial Adoption Cost..... 86
 - 4.2.5 COVID-19 86
- 4.3 Instrumentation and Automation 88
 - 4.3.1 Instruments Key to Market Share 88
 - 4.3.2 Bioinformatics Plays a Role 88
- 4.4 Diagnostic Technology Development 89
 - 4.4.1 Next Generation Sequencing Fuels a Revolution..... 90
 - 4.4.2 Impact of NGS on pricing..... 91
 - 4.4.3 Pharmacogenomics Blurs Diagnosis and Treatment..... 91
 - 4.4.4 CGES Testing, A Brave New World 92
 - 4.4.5 Biochips/Giant magneto resistance based assay..... 92
- 5 Liquid Biopsy Recent Developments94
 - 5.1 Recent Developments – Importance and How to Use This Section 95
 - 5.1.1 Importance of These Developments 95
 - 5.1.2 How to Use This Section..... 95
 - 5.2 Invitae to Expand Cancer Testing Portfolio..... 95
 - 5.3 Cancer Centre, Inivata Partner on Clinical Liquid Biopsy Studies..... 99
 - 5.4 IVBH Bio Takes Aim at With Liquid Biopsy Incubator..... 100

5.5	Molecular Health, Eone-Diagnomics Ink Liquid Biopsy Partnership	103
5.6	Delfi Diagnostics Looks To Fragmentation-Based Liquid Biopsy Tech	104
5.7	BillionToOne Adapting Fetal Dx Tech for Liquid Biopsy	107
5.8	EDGC to Expand Liquid Biopsy Space With Cell-Free DNA Platform.....	110
5.9	Liquid Biopsy Startup BioCaptiva Raises £1M in Seed Funding	113
5.10	Agilent Enters Liquid Biopsy Market with Resolution Biosciences Acquisition	113
5.11	Bio-Techne to Acquire Asuragen for up to \$320M	117
5.12	Personalis Broadens Liquid Biopsy Offering	118
5.13	Exact Sciences to Offer End-to-End Cancer Testing With Ashion Acquisition.....	121
5.14	Delfi Diagnostics Plans Multi-Cancer Screening Test.....	124
5.15	Menarini's CellSearch Shows Potential to Predict Breast Cancer Prognosis, Treatment Response.....	125
5.16	Liquid Biopsy NGS Panels - Diverse Test Claims.....	127
5.17	CMS Colon Cancer Screening Memo Bodes Well for Assays.....	133
5.18	Natera Liquid Biopsy Test Coverage to Expand	135
5.19	Freenome Closes Financing to Support Early Cancer Detection Trial	136
5.20	C\$2.6M Liquid Biopsy Initiative	137
5.21	NeoGenomics, Inivata Partner for Lung Cancer Liquid Biopsy	139
5.22	Liquid Biopsy Shows Promise as Screen for Cancers	140
5.23	Inivata launches RaDaR™ for the detection of residual disease and recurrence...	140
5.24	Liquid Biopsy Assay Detects 50+ Types of Cancer.....	141
5.25	Liquid Biopsy Study Confirms Concordance with Tissue Biopsy.....	144
5.26	Guardant Health Liquid Biopsy Expands Medicare Coverage.....	146
5.27	Aethlon Medical Lands Grant for Exosome Isolation Device	147

5.28 Biolidics to Develop Liquid Biopsy Breast Cancer Test 148

5.29 Liquid Biopsy Equal to Tissue to Indicate Immunotherapy Response..... 148

5.30 Exact Sciences buys Genomic Health 150

5.31 Multi-Gene Liquid Biopsy Breast Cancer Panel 152

5.32 Bio-Techne receives FDA breakthrough device for prostate cancer liquid biopsy.. 153

5.33 Thrive to Develop Earlier Detection of Multiple Cancer Types..... 154

5.34 Guardant Health Liquid Biopsy Test to be Covered by EviCore 156

5.35 Liquid biopsy combines Illumina's 'ultradeep' sequencing with Grail's machine learning 157

5.36 Biocept Partnership Offering for Liquid Biopsy Adds Several Key Services..... 159

5.37 Natera Commercializes Tumor Whole Exome Sequencing from Plasma..... 160

5.38 Sienna Buys Liquid Biopsy & Exosome Isolation Technology..... 161

6 Profiles of Key Players 163

6.1 Abbott Diagnostics 164

6.2 AccuraGen Inc. 166

6.3 Acuamark Diagnostics 167

6.4 Admera Health, LLC..... 168

6.5 Agena Bioscience, Inc. 170

6.6 Agilent..... 172

6.7 Amoy Diagnostics Co., Ltd..... 174

6.8 Anchor Dx..... 175

6.9 ANGLE plc..... 176

6.10 ApoCell, Inc..... 178

6.11 ArcherDx, Inc..... 179

6.12	Asuragen.....	180
6.13	AVIVA Biosciences	182
6.14	Baylor Miraca Genetics Laboratories	183
6.15	Beckman Coulter, Inc.	184
6.16	Becton, Dickinson and Company	186
6.17	BGI Genomics Co. Ltd	188
6.18	Bioarray Genetics.....	190
6.19	Biocartis.....	191
6.20	Biocept, Inc.....	192
6.21	Biodesix Inc.	193
6.22	BioFluidica.....	194
6.23	bioMérieux Diagnostics.....	195
6.24	Bioneer Corporation	197
6.25	Bio-Rad Laboratories, Inc.....	199
6.26	Bio-Techne	201
6.27	Bioview	203
6.28	Bolidics	205
6.29	Boreal Genomics.....	206
6.30	Caris Molecular Diagnostics	207
6.31	CellMax Life	208
6.32	Cepheid (now Danaher)	209
6.33	Chronix Biomedical.....	211
6.34	Circulogene.....	212
6.35	Clinical Genomics	213

6.36	Cynvenio.....	214
6.37	Cytolumina Technologies Corp.	215
6.38	CytoTrack.....	216
6.39	Datar Cancer Genetics Limited.....	217
6.40	Diagenode Diagnostics	218
6.41	Diagnologix LLC.....	219
6.42	Enzo Life Sciences, Inc.	220
6.43	Epic Sciences.....	222
6.44	Epigenomics AG.....	223
6.45	Eurofins Scientific	224
6.46	Exosome Diagnostics	227
6.47	Exosome Sciences.....	229
6.48	Fluidigm Corp	230
6.49	Fluxion Biosciences.....	232
6.50	Foundation Medicine	233
6.51	Freenome.....	234
6.52	GeneFirst Ltd.....	235
6.53	Genetron Health (Beijing) Co., Ltd.	236
6.54	Genomic Health.....	237
6.55	GILUPI Nanomedizin.....	239
6.56	Grail, Inc.....	240
6.57	Guardant Health	242
6.58	HansaBiomed	243
6.59	HeiScreen.....	244

6.60	Helomics.....	246
6.61	Horizon Discovery	248
6.62	iCellate.....	250
6.63	Illumina	251
6.64	Incell Dx.....	253
6.65	Inivata	254
6.66	Integrated Diagnostics	255
6.67	Janssen Diagnostics	256
6.68	MDNA Life SCIENCES, Inc.....	257
6.69	MDx Health	258
6.70	Menarini Silicon Biosystems.....	260
6.71	Millipore Sigma	261
6.72	Miltenyi Biotec	262
6.73	miR Scientific.....	263
6.74	Molecular MD.....	264
6.75	Myriad Genetics/Myriad RBM	265
6.76	NantHealth, Inc.	267
6.77	Natera	269
6.78	NeoGenomics	271
6.79	New Oncology	273
6.80	Novogene Bioinformatics Technology Co., Ltd.....	274
6.81	Oncocyte.....	276
6.82	OncoDNA	277
6.83	Oxford Nanopore Technologies	278

6.84	Perkin Elmer.....	280
6.85	Personal Genome Diagnostics.....	282
6.86	PrecisionMed.....	283
6.87	Promega.....	284
6.88	Qiagen Gmbh.....	286
6.89	Quidel.....	288
6.90	Rarecells SAS.....	290
6.91	RareCyte.....	292
6.92	Resolution Biosciences, Inc.....	293
6.93	Roche Molecular Diagnostics.....	294
6.94	Screecell.....	296
6.95	Siemens Healthineers.....	297
6.96	simfo GmbH.....	299
6.97	Singlera Genomics Inc.....	300
6.98	SRI International.....	301
6.99	Sysmex Inostics.....	303
6.100	Tempus Labs, Inc.....	304
6.101	Thermo Fisher Scientific Inc.....	305
6.102	Thrive Earlier Detection.....	307
6.103	Trovagene.....	308
6.104	Volition.....	309
7	The Global Market for Liquid Biopsy Diagnostics.....	310
7.1	Global Market Overview by Country.....	311
7.1.1	Table – Global Market by Country.....	311

- 7.1.2 Chart - Global Market by Country 312
- 7.2 Global Market by Cancer - Overview..... 313
 - 7.2.1 Table – Global Market by Cancer 313
 - 7.2.2 Chart – Global Market by Cancer – Base/Final Year Comparison 314
 - 7.2.3 Chart – Global Market by Cancer – Base Year 315
 - 7.2.4 Chart – Global Market by Cancer – End Year 316
 - 7.2.5 Chart – Global Market by Cancer – Share by Year 317
 - 7.2.6 Chart – Global Market by Cancer – Segments Growth..... 318
- 7.3 Global Market by Usage - Overview 319
 - 7.3.1 Table – Global Market by Usage..... 319
 - 7.3.2 Chart – Global Market by Usage – Base/Final Year Comparison 320
 - 7.3.3 Chart – Global Market by Usage – Base Year..... 321
 - 7.3.4 Chart – Global Market by Usage – End Year 322
 - 7.3.5 Chart – Global Market by Usage – Share by Year..... 323
 - 7.3.6 Chart – Global Market by Usage – Segments Growth 324
- 7.4 Global Market by Place - Overview 325
 - 7.4.1 Table – Global Market by Place..... 325
 - 7.4.2 Chart – Global Market by Place – Base/Final Year Comparison 326
 - 7.4.3 Chart – Global Market by Place – Base Year..... 327
 - 7.4.4 Chart – Global Market by Place – End Year 328
 - 7.4.5 Chart – Global Market by Place – Share by Year..... 329
 - 7.4.6 Chart – Global Market by Place – Segments Growth 330
- 7.5 Global Market by Marker - Overview 331
 - 7.5.1 Table – Global Market by Marker 331

- 7.5.2 Chart – Global Market by Marker – Base/Final Year Comparison 332
- 7.5.3 Chart – Global Market by Marker – Base Year 333
- 7.5.4 Chart – Global Market by Marker – End Year 334
- 7.5.5 Chart – Global Market by Marker – Share by Year..... 335
- 7.5.6 Chart – Global Market by Marker – Segments Growth 336
- 7.6 Global Market by Product - Overview 337
 - 7.6.1 Table – Global Market by Product..... 337
 - 7.6.2 Chart – Global Market by Product – Base/Final Year Comparison..... 338
 - 7.6.3 Chart – Global Market by Product – Base Year..... 339
 - 7.6.4 Chart – Global Market by Product – End Year 340
 - 7.6.5 Chart – Global Market by Product – Share by Year 341
 - 7.6.6 Chart – Global Market by Product – Segments Growth 342
- 8 Global Liquid Biopsy Diagnostic Markets – By Cancer.....343
 - 8.1 Breast 344
 - 8.1.1 Table Breast – by Country 344
 - 8.1.2 Table Breast – by Country, Price..... 345
 - 8.1.3 Table Breast – by Country Volume..... 346
 - 8.1.4 Chart - Breast Growth 347
 - 8.2 Colorectal..... 348
 - 8.2.1 Table Colorectal – by Country 348
 - 8.2.2 Table Colorectal – by Country, Price..... 349
 - 8.2.3 Table Colorectal – by Country, Volume 350
 - 8.2.4 Chart - Colorectal Growth..... 351
 - 8.3 Cervical..... 352

8.3.1	Table Cervical – by Country	352
8.3.2	Table Cervical – by Country, Price.....	353
8.3.3	Table Cervical – by Country, Volume.....	354
8.3.4	Chart - Cervical Growth	355
8.4	Lung.....	355
8.4.1	Table Lung – by Country	356
8.4.2	Table Lung – by Country, Price.....	357
8.4.3	Table Lung – by Country, Volume.....	358
8.4.4	Chart - Lung Growth	359
8.5	Prostate.....	360
8.5.1	Table Prostate – by Country	360
8.5.2	Table Prostate – by Country, Price	361
8.5.3	Table Prostate – by Country, Volume	362
8.5.4	Chart – Prostate Growth	363
8.6	Other	364
8.6.1	Table Other – by Country	364
8.6.2	Table Other – by Country, Price	365
8.6.3	Table Other – by Country, Volume	366
8.6.4	Chart - Other Growth.....	367
9	Global Liquid Biopsy Diagnostic Markets – by Usage.....	368
9.1	Screening.....	369
9.1.1	Table Screening – by Country	369
9.2	Chart - Screening Growth	370
9.3	Diagnostic.....	371

- 9.3.1 Table Diagnostic – by Country 371
- 9.3.2 Chart - Diagnostic Growth..... 372
- 9.4 Therapy 373
 - 9.4.1 Table Therapy – by Country..... 373
 - 9.4.2 Chart - Therapy Growth 374
- 9.5 Monitor 375
 - 9.5.1 Table Monitor – by Country 375
 - 9.5.2 Chart - Monitor Growth..... 376
- 10 Global Liquid Biopsy Diagnostic Markets – by Place377
 - 10.1 Hospital Lab 378
 - 10.1.1 Table Hospital Lab – by Country 378
 - 10.1.2 Chart - Hospital Lab Growth..... 379
 - 10.2 Lab Service 380
 - 10.2.1 Table Lab Service – by Country 380
 - 10.2.2 Chart - Lab Service Growth 381
 - 10.3 Lab Outpatient..... 382
 - 10.3.1 Table Lab Outpatient – by Country 382
 - 10.3.2 Chart - Lab Outpatient Growth 383
 - 10.4 Other Lab..... 384
 - 10.4.1 Table Other Lab – by Country 384
 - 10.4.2 Chart - Other Lab Growth 385
- 11 Global Liquid Biopsy Diagnostic Markets – by Marker386
 - 11.1 Circulating Tumor Cell..... 387
 - 11.1.1 Table Circulating Tumor Cell – by Country..... 387

- 11.1.2 Chart - Circulating Tumor Cell Growth 388
- 11.2 Cell Free DNA 389
 - 11.2.1 Table Cell Free DNA – by Country..... 389
 - 11.2.2 Chart - Cell Free DNA Growth..... 390
- 11.3 Vesicle 391
 - 11.3.1 Table Vesicle – by Country 391
 - 11.3.2 Chart - Vesicle Growth..... 392
- 11.4 Other Marker 393
 - 11.4.1 Table Other Marker – by Country..... 393
 - 11.4.2 Chart - Other Marker Growth 394
- 12 Global Liquid Biopsy Diagnostic Markets – by Product.....395
 - 12.1 Kits..... 396
 - 12.1.1 Table Kits – by Country 396
 - 12.1.2 Chart - Kits Growth 397
 - 12.2 Instruments..... 398
 - 12.2.1 Table Instruments – by Country 398
 - 12.2.2 Chart - Instruments Growth..... 399
 - 12.3 Service..... 400
 - 12.3.1 Table Service – by Country 400
 - 12.3.2 Chart - Service Growth 401
- 13 Appendices.....402
 - 13.1 United States Medicare System: 2021 Clinical Laboratory Fees Schedule..... 402

Table of Tables

Table 1 Market Players by Type 44

Table 2 Biopsy Sites 52

Table 3 Advantages of Liquid Biopsy in Screening Market 71

Table 4 Outlook - Phases of Liquid Biopsy Adoption by Year..... 74

Table 5 Five Factors Driving Growth 82

Table 6 Factors Limiting Growth 85

Table 7 Key Diagnostic Laboratory Technology Trends 89

Table 8 Next Generation Sequencing Technologies – Speed and Cost 90

Table 9 - Global Market by Region 311

Table 10 Global Market by Cancer 313

Table 11 Global Market by Usage..... 319

Table 12 Global Market by Place..... 325

Table 13 Global Market by Marker..... 331

Table 14 Global Market by Product 337

Table 15 Breast by Country 344

Table 16 Breast by Country Price..... 345

Table 17 Breast by Country Volume..... 346

Table 18 Colorectal by Country 348

Table 19 Colorectal by Country Price 349

Table 20 Colorectal by Country Volume 350

Table 21 Cervical by Country 352

Table 22 Cervical by Country Price..... 353

Table 23 Cervical by Country Volume..... 354

Table 24 Lung by Country 356

Table 25 Lung by Country Price..... 357

Table 26 Lung by Country Volume..... 358

Table 27 Prostate by Country 360

Table 28 Prostate by Country Price 361

Table 29 Prostate by Country Volume 362

Table 30 Other by Country..... 364

Table 31 Other by Country Price 365

Table 32 Other by Country Volume 366

Table 33 Screening by Country 369

Table 34 Diagnostic by Country 371

Table 35 Therapy by Country..... 373

Table 36 Monitor by Country 375

Table 37 Hospital Lab by Country 378

Table 38 Lab Service by Country..... 380

Table 39 Lab Outpatient by Country 382

Table 40 Other Lab by Country 384

Table 41 Circulating Tumor Cell by Country 387

Table 42 Cell Free DNA by Country..... 389

Table 43 Vesicle by Country 391

Table 44 Other Marker by Country..... 393

Table 45 Kits by Country..... 396

Table 46 Instruments by Country	398
Table 47 Service by Country	400
Table 48 2021 Clinical Lab Fee Schedule	402

Table of Figures

Figure 1 Global Healthcare Spending 40

Figure 2 The Lab Test Pie 41

Figure 3 Comparison of Liquid Biopsy Classes 56

Figure 4 Characteristics of Different Vesicle Types 67

Figure 5 Percentage of World Population Over 65 84

Figure 6 Global Market Regional Share Chart 312

Figure 7 Global Market by Cancer - Base vs. Final 314

Figure 8 Global Market by Cancer Base Year 315

Figure 9 Global Market by Cancer End Year 316

Figure 10 Cancer Share by Year 317

Figure 11 Cancer Segments Growth 318

Figure 12 Global Market by Usage - Base vs. Final 320

Figure 13 Global Market by Usage Base Year 321

Figure 14 Global Market by Usage End Year 322

Figure 15 Usage Share by Year 323

Figure 16 Usage Segments Growth 324

Figure 17 Global Market by Place - Base vs. Final 326

Figure 18 Global Market by Place Base Year 327

Figure 19 Global Market by Place End Year 328

Figure 20 Place Share by Year 329

Figure 21 Place Segments Growth 330

Figure 22 Global Market by Marker - Base vs. Final 332

Figure 23 Global Market by Marker Base Year..... 333

Figure 24 Global Market by Marker End Year 334

Figure 25 Marker Share by Year..... 335

Figure 26 Marker Segments Growth 336

Figure 27 Global Market by Product - Base vs. Final..... 338

Figure 28 Global Market by Product Base Year 339

Figure 29 Global Market by Product End Year..... 340

Figure 30 Product Share by Year 341

Figure 31 Product Segments Growth 342

Figure 32 Breast Growth 347

Figure 33 Colorectal Diagnostics Growth 351

Figure 34 Cervical Growth 355

Figure 35 Lung Growth 359

Figure 36 Prostate Growth..... 363

Figure 37 Other Growth..... 367

Figure 38 Screening Growth 370

Figure 39 Diagnostic Growth 372

Figure 40 Therapy Growth..... 374

Figure 41 Monitor Growth..... 376

Figure 42 Hospital Lab Growth..... 379

Figure 43 Lab Service Growth..... 381

Figure 44 Lab Outpatient Growth 383

Figure 45 Other Lab Growth 385

Figure 46 Circulating Tumor Cell Growth 388

Figure 47 Cell Free DNA Growth..... 390

Figure 48 Vesicle Growth 392

Figure 49 Other Marker Growth 394

Figure 50 Kits Growth 397

Figure 51 Instruments Growth 399

Figure 52 Service Growth 401